CRON Cronos Group Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1656472 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY55.8%
TTM net income YoY60.2%
TTM EPS YoY60.0%
Revenue 3-yr CAGR34.2%
Net income 3-yr CAGR—
Margins
Gross margin46.6%
Operating margin3.4%
Net margin28.0%
FCF margin31.7%
EBITDA margin7.4%
Returns
ROE5.4%
ROA4.9%
ROIC (approx.)1.5%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets6.1%
Debt / equity0.00x
Current ratio12.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue7.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $146.59M | $117.61M |
| Gross profit | $62.76M | $25.20M |
| R&D expense | $4.45M | $4.23M |
| SG&A expense | $42.00M | $46.51M |
| Operating income | -$17.39M | -$76.53M |
| Pretax income | -$17.12M | $36.59M |
| Income tax | -$14.19M | -$3.44M |
| Net income | -$9.45M | $41.08M |
| EBITDA | -$3.16M | -$67.19M |
| EPS (basic) | -0.02 | 0.11 |
| EPS (diluted) | -0.02 | 0.11 |
| Weighted avg. shares (diluted) | 383.47M | 385.56M |
| Balance sheet | ||
| Cash & equivalents | $791.79M | $858.80M |
| Short-term investments | $40.00M | $0 |
| Receivables | $34.10M | $15.46M |
| Inventory | $46.75M | $33.15M |
| Current assets | $944.09M | $936.11M |
| PP&E, net | $145.87M | $133.19M |
| Goodwill | $66.48M | $63.45M |
| Intangibles | $8.89M | $11.26M |
| Total assets | $1.20B | $1.17B |
| Current liabilities | $48.19M | $49.70M |
| Total liabilities | $54.18M | $55.33M |
| Shareholders' equity | $1.09B | $1.06B |
| Shares outstanding | 381.59M | 382.53M |
| Cash flow statement | ||
| Operating cash flow | $25.87M | $18.84M |
| Capital expenditure | $25.72M | $12.41M |
| Free cash flow | $149,000 | $6.43M |
| Investing cash flow | -$76.56M | $175.15M |
| Financing cash flow | -$19.91M | -$1.23M |
| Depreciation & amortization | $14.23M | $9.34M |
| Stock-based compensation | $7.05M | $8.70M |
| Share buybacks | $9.74M | $0 |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.